Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Sargramostim Inhalation for COVID-19 Pneumonia
NCT04642950Phase 3Completed
- Sponsor
- Nobelpharma Co., Ltd.
- Start
- Dec 2020
- Primary completion
- Oct 2021
- Modality
- Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
A Phase 3 trial of sargramostim in coronavirus disease 2019 (COVID-19), sponsored by Nobelpharma Co., Ltd.. Started Dec 2020; status: completed.
02
Drugs
sargramostim
03
Conditions
coronavirus disease 2019 (COVID-19)
Beyond the preview
Go deeper on NCT04642950.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04642950.